Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Drugs In Development, 2024 report and make more profitable business decisions.
Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas that originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include a lump or swelling in the in the soft tissue, numbness, burning, tingling or pins and needles, weakness of the affected muscles, and dizziness or loss of balance. Treatment includes surgery, radiotherapy, and chemotherapy.
The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) drugs in development market research report provide comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 32 molecules, with 32 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncAdaptimmune Therapeutics Plc
Advenchen Laboratories LLC
Aldeyra Therapeutics Inc
Apexian Pharmaceuticals Inc
Ascentage Pharma Group International
AstraZeneca Plc
BeiGene Ltd
Bristol-Myers Squibb Co
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Eisai Co Ltd
F. Hoffmann-La Roche Ltd
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Karyopharm Therapeutics Inc
Kibio Inc
Merck & Co Inc
Mirati Therapeutics Inc
Moleculin Biotech Inc
Novartis AG
Oncomatryx Biopharma SL
Open Therapeutics LLC
Otsuka Pharmaceutical Co Ltd
Pharma Mar SA
Plexxikon Inc
Shenzhen Chipscreen Biosciences Co Ltd
Sorrento Therapeutics Inc
Tango Therapeutics Inc
Vyriad Inc
Table of Contents
Table
Figures
Frequently asked questions